The study, published in BMC Genomics by Aitor Almanza of Navarrabiomed and colleagues, addresses a gap that has widened as genomic medicine has scaled up. Next-generation sequencing has transformed precision medicine, but the analytical workflows behind it have become increasingly complex, involving multiple extraction steps, library preparations, batching events and platform transfers. Each handoff is an opportunity for error. While the frequency of sample misidentification may be low, the researchers note that the potential negative outcomes are worrying, particularly in clinical contexts where a wrong sample match can influence diagnosis or treatment decisions. Existing SNP-based quality control solutions, they argue, tend to rely on non-coding genetic markers or require advanced technologies that many laboratories do not have, leaving a need for small, robust panels that are portable across technologies, compatible with diagnostic panels, applicable across diverse populations and straightforward to implement in a wet lab.

The core idea behind the new panel is elegantly simple. Every person carries millions of genetic variants, and the specific combination of variants at a carefully chosen set of positions acts like a molecular fingerprint that is essentially unique to an individual. If a laboratory genotypes those positions in a sample at the start of a workflow and again at the end, or compares a sequencing result against a reference profile collected earlier, any mismatch immediately flags a possible sample swap or contamination. The challenge lies in choosing which variants to include. The markers must be highly discriminant, meaning that the chance of two unrelated people sharing the same profile is vanishingly small. They must also be compatible across platforms, so that a profile generated on a sequencer can be compared with one generated on a qPCR machine, and they must work reliably in populations around the world rather than being calibrated to a single ancestry group.

To build the panel, the team applied a stringent filtering pipeline designed to identify highly discriminant, cross-platform compatible genetic markers supported by predesigned TaqMan assays. TaqMan assays are a widely used qPCR genotyping chemistry in which fluorescent probes report which allele is present at a specific position, making the technology a staple of clinical molecular laboratories. By restricting the candidate markers to SNPs that already have validated, commercially available TaqMan assays, the researchers ensured that any laboratory with standard qPCR infrastructure could adopt the barcode without developing new reagents from scratch. They also prioritized SNPs that are already present in clinical sequencing panels, a decision with important practical consequences: it means the barcode can often be read directly from data that clinical laboratories are already generating, without any additional sequencing effort.

Population applicability was a central design criterion. A barcode that discriminates well in European populations but poorly in East Asian or African populations would be of limited use in the diverse patient cohorts of modern medicine. The researchers therefore prioritized markers with broad applicability across world populations, drawing on allele frequency data to ensure that the panel retains its discriminatory power regardless of the ancestry of the person being tested. This focus distinguishes the panel from earlier identity-testing approaches that were often optimized for specific populations or that relied on markers whose behavior across ancestries was less well characterized. The result is a barcode intended to be genuinely portable, both technologically and demographically.

The validation of the panel drew on the NAGENDATA cohort, a collection of neuropathology samples from Navarra, Spain, gathered under informed consent for research use and approved by the Research Ethics Committee of Navarra. The team used whole-genome sequencing data from 150 samples in the cohort to establish reference profiles and then cross-validated the barcode with qPCR genotyping. The numbers reported are striking. The full 44-SNP panel demonstrates exceptional discriminatory power, with theoretical cumulative random match probabilities ranging from 2.43 times ten to the power of minus nineteen in European populations to 9.37 times ten to the power of minus eighteen in East Asian populations. In plain terms, the probability that two unrelated individuals share the same 44-SNP profile is so small, on the order of one in many quintillions, that a matching profile can be treated as conclusive evidence of identity for practical purposes.

Cross-platform performance is where the panel earns its clinical credentials. When the researchers compared profiles generated by next-generation sequencing with those generated by qPCR, they found 99 percent concordance between the two technologies. That level of agreement matters because the whole point of a portable barcode is that a profile generated in one laboratory, on one instrument, can be trusted when compared against a profile generated elsewhere, on a different instrument, perhaps years later. A barcode that produced different answers depending on the platform would generate false alarms and erode confidence. The high concordance indicates that the selected SNPs genotype cleanly and consistently across chemistries, a property that reflects careful marker selection as much as analytical rigor.

The panel did not merely perform well in theory; it caught real errors. Combined within-platform and cross-platform analyses successfully identified three cases of sample mislabelling in the NAGENDATA collection. Those three detections, in a cohort of 150 samples, illustrate the kind of silent failures that can lurk in even well-managed biobanks and sequencing facilities. Without an independent genetic check, such mislabelled samples would have propagated through downstream analyses, potentially associating genomic data with the wrong individual and contaminating scientific conclusions. In a clinical workflow, the same failure could have far more serious consequences. The demonstration that a compact barcode can surface these errors retroactively, using data already on hand, underscores the practical value of the approach.

The researchers describe the result as a robust, ready-to-deploy SNP barcode that bridges next-generation sequencing and wet-lab workflows, enabling retrospective sample authentication across sequencing platforms and qPCR systems. The retrospective dimension deserves emphasis. Because many clinical sequencing panels already include the barcode SNPs, laboratories can often authenticate historical samples by extracting the relevant positions from existing sequencing files and comparing them against qPCR profiles or against other sequencing data. This opens the door to auditing past datasets for sample integrity issues without re-extracting DNA or re-running expensive assays, a capability that could be valuable for quality assurance programs, biobank certification and the growing movement toward reproducibility in genomics.

The design choices also reflect the regulatory and economic realities of clinical genomics. Sample tracking and data integrity sit at the intersection of privacy frameworks such as the GDPR and HIPAA, and laboratories need solutions that protect patient identity while verifying it. A 44-SNP barcode is deliberately minimal: it contains far too little information to reconstruct a person’s appearance, health risks or ancestry in any meaningful detail, yet more than enough to distinguish one individual from another. Combined with cost-effective implementation on equipment that most molecular laboratories already own, the panel lowers the barrier to routine sample authentication. As sequencing becomes ever more embedded in research and clinical routine, tools like this barcode point toward a future where every genomic dataset carries an internal, verifiable proof of its own provenance, quietly guarding against the swapped tubes and mislabelled plates that no laboratory is immune to.

Subject of Research: A TaqMan-compatible 44-SNP panel for cross-platform genetic sample authentication and tracking

Article Title: A TaqMan-compatible 44-SNP barcode for robust sample tracking in research and clinical settings

Article References: A TaqMan-compatible 44-SNP barcode for robust sample tracking in research and clinical settings. (n.d.). https://doi.org/10.1186/s12864-026-13282-w

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13282-w

Keywords: sample tracking, SNP barcode, TaqMan, genomics, next-generation sequencing, qPCR, whole-genome sequencing, biobank, data integrity, precision medicine, sample mislabelling, genotyping

The funding establishes the Polysubstance Addiction Research Center, or PARC, a multidisciplinary center led by Olivier George, PhD, professor of psychiatry at UC San Diego School of Medicine. The center assembles investigators from psychiatry, medicine, obstetrics and gynecology and reproductive sciences, and computational biology and bioinformatics, in partnership with the Veterans Affairs San Diego Healthcare System. Its stated mission is to uncover the biological factors that contribute to addiction across multiple substances, rather than studying one drug class at a time.

George, who directs PARC, argues that the traditional division of the field does not reflect how addiction actually occurs. People frequently use more than one substance, he notes, so researchers need to understand what these substances have in common as well as what makes them different. By bringing psychostimulant research — a category that includes cocaine, which speeds up activity in the central nervous system — together with opioid and alcohol research under one organizational roof, the center hopes to identify biological mechanisms that may be shared across substances and others that are specific to particular drug classes.

The scientific scope of the center is deliberately broad. PARC will focus its experimental work on cocaine, oxycodone, alcohol, and the combination of cocaine and oxycodone, using a coordinated research strategy in which the same questions are asked across all four exposure conditions. Rather than examining a single biological system in isolation, the investigators will study behavior alongside changes in brain networks, gene activity, and processes involving the immune system, metabolism, and the gut-brain connection. The goal is to understand why some individuals develop more severe addiction-related behaviors than others, and to do so by looking at multiple biological systems simultaneously.

Central to this effort is what the center calls its One-Individual Multiscale Atlas, a framework for integrating information that ranges from genes and individual cells to brain circuits, peripheral organs, and behavior. In practical terms, the atlas is meant to connect measurements made at one biological level with measurements made at another: how a change in gene expression within a specific type of brain cell relates to altered communication across a neural network, and how both relate to observable behavior. Findings generated in the laboratory will then be compared with human genetic, brain imaging, and other biological datasets to determine whether the patterns observed in preclinical models align with variation seen in people.

Abraham Palmer, PhD, professor and vice chair of basic research in the Department of Psychiatry at UC San Diego School of Medicine, emphasizes the genetic dimension of this approach. Decades of research have established that genetic differences among individuals contribute to risk for addiction, and Palmer describes PARC as using cutting-edge techniques to understand how those individual differences shape addiction risk at the molecular, cellular, and brain circuit levels. The multiscale design is intended to bridge the gap between statistical genetic associations and the biological mechanisms those associations may point toward.

The center’s work is organized into three interconnected research projects. The first, a brain connectomics project, will examine how addiction changes the organization and communication of brain networks — asking, in effect, whether repeated exposure to cocaine, oxycodone, alcohol, or their combination produces measurable shifts in how regions of the brain talk to one another. The second, a brain transcriptomics project, will study changes in gene activity within specific types of brain cells, a level of resolution that has become possible with modern single-cell and cell-type-specific molecular methods. The third, a gut-vagus multiomics project, will investigate how the gut and the vagus nerve — the cranial nerve that connects the brain with organs throughout the body — may influence addiction-related behaviors, reflecting growing scientific interest in the role of peripheral physiology and the microbiome-gut-brain axis in neuropsychiatric conditions.

Together, these projects support the center’s first formal aim: identifying biological markers associated with vulnerability to addiction-related behaviors. Advanced computational and machine-learning methods will be used to integrate the different types of data the projects generate and to identify patterns that may help explain differences in addiction severity. The second aim goes a step further, moving from correlation to causation. Researchers will use medications and other interventions to test whether potential biological targets identified through the center’s research — including pathways involved in cellular stress, immune signaling, and communication between the gut and the brain — actually influence addiction-related behavior when manipulated. As George puts it, the goal is to go beyond simply finding a biological difference associated with addiction and to test whether changing that biological process changes the behavior itself, an approach he argues is more likely to yield targets that translate into new treatments.

The third aim is infrastructural. PARC will expand an addiction biobank that already contains more than 40,000 specimens collected from studies of addiction-related behaviors involving cocaine, oxycodone, and alcohol, a resource that has supported 75 external research projects to date. The center will also provide researchers with access to standardized behavioral models, computational tools, and shared datasets, with data deposited in National Institutes of Health repositories to support reproducibility and allow other laboratories to build on the center’s findings. In this respect, PARC is designed not only as a research program but as a national resource for addiction science.

The new center formalizes and expands a collaboration that has been building at UC San Diego for six years. During that period, PARC investigators have worked across more than a dozen laboratories, producing hundreds of publications and developing shared research resources. Barbara Jung, MD, associate vice chancellor and dean of UC San Diego School of Medicine, describes the award as a recognition of George’s leadership and his vision for bringing researchers across disciplines to address the complexities of addiction, and says the creation of PARC strengthens the school’s ability to lead collaborative research that can deepen understanding of addiction and help identify new approaches to prevention and treatment. By connecting biological information across multiple levels and bridging the historical divide between alcohol and drug research, PARC aims to move the field from isolated observations toward an integrated account of why addiction develops, why some people are more vulnerable than others, and why relapse occurs.

Subject of Research: A NIDA-funded multidisciplinary center studying the shared biology of polysubstance addiction across cocaine, oxycodone, and alcohol

Article Title: UC San Diego receives $12.6 million award to launch a new polysubstance addiction research center

Article References: UC San Diego receives $12.6 million award to launch a new polysubstance addiction research center. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: polysubstance addiction, NIDA, UC San Diego, Olivier George, brain connectomics, transcriptomics, gut-brain axis, vagus nerve, cocaine, oxycodone, alcohol use disorder, biobank

The concept of heritability sits at the heart of quantitative genetics. Twin and family studies have long established that traits ranging from height and body mass index to blood cell counts, cholesterol levels and susceptibility to schizophrenia are substantially inherited. Yet when geneticists sum up the effects of the millions of single-nucleotide polymorphisms captured in genome-wide association studies, or GWAS, they typically recover only a fraction of the heritability estimated from family data — a shortfall famously dubbed the missing heritability. Explanations have included rare variants, gene-gene interactions, gene-environment effects and imperfect measurement. The new work adds a powerful quantitative argument that a major piece of the missing puzzle has been hiding in plain sight, in the form of large DNA rearrangements that standard genotyping arrays and short-read sequencing struggle to detect.

Structural variants are, in many respects, the heavyweight class of genetic variation. A single deletion can remove an entire gene or a regulatory region controlling several genes; a duplication can multiply gene dosage; an inversion can disrupt gene order and alter how regulatory elements connect to their targets. Decades of cytogenetics and, more recently, long-read sequencing have shown that individual structural variants often exert effects on gene expression and phenotype that are disproportionately large compared with their frequency in the population. What remained unknown was whether this per-variant potency translates into a meaningful share of genome-wide heritability when aggregated across the whole genome and across the full spectrum of common human traits. Answering that question required a methodological innovation, because the standard statistical machinery of GWAS was never designed with structural variants in mind.

MiXeR-SV, the tool introduced by the Oslo-led team, bridges that gap by integrating long-read-derived structural variant catalogs — reference maps of deletions, duplications and other rearrangements assembled from advanced sequencing technologies — with GWAS summary statistics, the aggregated association data that most large genetic studies publish. Rather than requiring raw genome sequences from hundreds of thousands of individuals, the method works from the summary level, estimating how much of the genetic signal in a GWAS can be attributed to variants that are correlated, or in linkage disequilibrium, with structural variants. The framework extends the earlier MiXeR platform, which the group developed to quantify the number of causal variants underlying complex traits, and adds a partitioning layer that separates the heritability contribution of structural variants from that of ordinary single-nucleotide variants.

The researchers applied the method to 105 complex traits drawn from large-scale biobank GWAS resources. Using a stringent Bonferroni-corrected significance threshold of P less than 4.8 times ten to the minus four, they identified 31 traits showing significant enrichment of heritability in structural variants. The pattern was not uniform across biology. Enrichment was most extensive for hematological traits such as blood cell counts, for metabolic traits and biomarkers, and for cancer-related phenotypes. Neuropsychiatric and cardiometabolic traits showed enrichment as well, but in a more trait-specific fashion, with particular structural variant classes contributing in particular contexts. All anthropometric traits examined — measures of body size and proportions — showed evidence of structural variant contribution, though with modest effect sizes, consistent with the highly polygenic architecture in which thousands of variants each nudge the trait slightly.

A central concern for any study relying on reference catalogs of structural variants is whether the results depend on the particular technology used to build the catalog. Long-read sequencing platforms, such as those producing very long continuous DNA reads, and graph-based pangenome approaches detect overlapping but not identical sets of rearrangements, each with its own biases. To address this, the team repeated their analyses with two independent structural variant reference panels built from complementary long-read and graph-based catalogs. The results were remarkably consistent: 93.5 percent of the traits that reached significance with one panel were also significant with the other. This cross-technology agreement substantially strengthens the case that the observed enrichment reflects genuine biology rather than an artifact of any single variant-calling pipeline.

Perhaps the most consequential finding concerns the missing heritability problem directly. When the researchers incorporated structural variant architecture into their heritability models, the total heritability estimates for enriched phenotypes consistently increased. In other words, allowing for structural variants did not merely reshuffle a fixed pie of heritability — it enlarged the pie, recovering genetic signal that pure SNP-based models had left on the table. Moreover, the proportion of heritability attributable to structural variants correlated with the gap between SNP-based heritability estimates and the higher heritability estimates from twin studies across traits. This correlation suggests that a measurable portion of the long-standing discrepancy between family-based and molecular estimates of heritability can be explained by large rearrangements that conventional GWAS genotyping fails to capture well.

The team also tested whether the findings hold across human populations, an essential check in a field where most genetic research has historically focused on European ancestry cohorts. Cross-ancestry replication in Biobank Japan, one of the largest biobanks in Asia, confirmed the enrichment patterns observed in the discovery analyses, indicating that the disproportionate contribution of structural variants to complex trait heritability is not an artifact of one population’s demographic history or linkage disequilibrium structure. Supplementary analyses extended the validation further, including sensitivity tests of the linkage disequilibrium reference panels, simulations across varying GWAS sample sizes, and replication in the Taiwan Biobank, all of which supported the robustness of the core result.

The technical achievement underlying these findings is worth emphasizing. Structural variants are difficult to genotype at scale: their breakpoints vary between individuals, their sequence content can be complex, and short-read sequencing — the workhorse of most GWAS — cannot resolve many of them unambiguously. By leveraging the growing public catalogs produced by long-read sequencing consortia and pangenome projects, and by developing statistical machinery that operates on GWAS summary statistics rather than raw sequence data, MiXeR-SV makes it feasible to ask genome-wide questions about structural variant contributions using data that already exist. The authors note that the study used only publicly available data with existing ethical approvals, and that the framework’s estimates were calibrated through simulations covering linkage disequilibrium panel configurations and GWAS sample sizes.

The implications reach into two of the most active areas of human genetics. For genetic prediction, the results suggest that polygenic risk scores built exclusively from single-nucleotide variants systematically omit a component of inherited risk, and that incorporating structural variant information could improve prediction for traits where enrichment is strong, such as blood cell traits and certain biomarkers. For fine-mapping — the effort to pinpoint the causal variants behind association signals — the findings indicate that structural variants should be explicitly included as candidates, since a GWAS signal tagged by common SNPs may in fact be driven by a nearby deletion or duplication with a much larger effect on nearby genes. As long-read sequencing becomes cheaper and structural variant catalogs grow more complete across diverse ancestries, the quantitative framework introduced here offers a way to track how much of the genome’s influence on human health has been waiting in its largest and least-charted variations.

Subject of Research: Contribution of structural variants to the heritability of human complex traits

Article Title: Structural variants contribute substantially to complex trait heritability

Article References: Nguyen, D. T., Shadrin, A. A., Parker, N., Fuhrer, J., Vo, N. S., Dale, A. M., Andreassen, O. A., & Frei, O. (2026). Structural variants contribute substantially to complex trait heritability. Genome Biology. https://doi.org/10.1186/s13059-026-04248-y

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04248-y

Keywords: structural variants, heritability, GWAS, long-read sequencing, genetic architecture, complex traits, missing heritability, MiXeR-SV, polygenic traits, biobank, cross-ancestry replication, Genome Biology